Active substance Linezolid (C16H20FN3O4)
US Brand Zyvox, Zyvoxid
IN Brand Linox, other
Manufacturing by Unichem, India
Strength 600mg
Form release blister 4 or 10 tablets
Estimated shipping time 7 – 18 days (Depending from the Country)
Availability, Prices & Order through request form
Make request

 

DescriptionDosageSide Effects

The main use of linezolid is the treatment of severe infections caused by Gram-positive bacteria that are resistant to other antibiotics; it should not be used against bacteria that are sensitive to drugs with a narrower spectrum of activity, such as penicillins and cephalosporins. In both the popular press and the scientific literature, linezolid has been called a “reserve antibiotic”—one that should be used sparingly so that it will remain effective as a drug of last resort against potentially intractable infections.

In the United States, the indications for linezolid use approved by the U.S. Food and Drug Administration (FDA) are the treatment of vancomycin-resistant Enterococcus faeciuminfections, with or without bacterial invasion of the bloodstream; nosocomial pneumonia (hospital-acquired) and community-acquired pneumonia caused by S. aureus or S. pneumoniae; complicated skin and skin structure infections (cSSSI) caused by susceptible bacteria, including diabetic foot infection, unless complicated by osteomyelitis (infection of the bone and bone marrow); and uncomplicated skin and soft tissue infections caused by S. pyogenes or S. aureus. The manufacturer advises against the use of linezolid for community-acquired pneumonia or uncomplicated skin and soft tissue infections caused by MRSA. In the United Kingdom, pneumonia and cSSSIs are the only indications noted in the product labeling. 

Linezolid appears to be as safe and effective for use in children and newborns as it is in adults.

600 mg IV or orally every 12 hours

Duration of therapy:
-Pneumonia: 10 to 14 consecutive days
-Vancomycin-resistant Enterococcus faecium infections: 14 to 28 consecutive days

Uses: For the treatment of community-acquired pneumonia due to Streptococcus pneumoniae (including cases with concurrent bacteremia) or Staphylococcus aureus (methicillin-susceptible isolates only); for the treatment of nosocomial pneumonia due to S aureus (methicillin-susceptible and -resistant isolates) or S pneumoniae; for the treatment of vancomycin-resistant E faecium infections (including cases with concurrent bacteremia)

600 mg IV or orally every 12 hours

Duration of therapy:
-Pneumonia: 10 to 14 consecutive days
-Vancomycin-resistant Enterococcus faecium infections: 14 to 28 consecutive days

Uses: For the treatment of community-acquired pneumonia due to Streptococcus pneumoniae (including cases with concurrent bacteremia) or Staphylococcus aureus (methicillin-susceptible isolates only); for the treatment of nosocomial pneumonia due to S aureus (methicillin-susceptible and -resistant isolates) or S pneumoniae; for the treatment of vancomycin-resistant E faecium infections (including cases with concurrent bacteremia)

600 mg IV or orally every 12 hours

Duration of therapy:
-Pneumonia: 10 to 14 consecutive days
-Vancomycin-resistant Enterococcus faecium infections: 14 to 28 consecutive days

Uses: For the treatment of community-acquired pneumonia due to Streptococcus pneumoniae (including cases with concurrent bacteremia) or Staphylococcus aureus (methicillin-susceptible isolates only); for the treatment of nosocomial pneumonia due to S aureus (methicillin-susceptible and -resistant isolates) or S pneumoniae; for the treatment of vancomycin-resistant E faecium infections (including cases with concurrent bacteremia)

Diarrhea, headache, nausea, vomiting, or dizziness may occur. If any of these effects last or get worse, tell your doctor or pharmacist promptly.